Skip to NavigationSkip to content

President trump

Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020

Multiple drugmakers, including Pfizer, Sanofi and GlaxoSmithKline, plan to increase US list prices on more than 200 drugs in the United States.

Most price increases are expected to be announced later this week. Most will be below 10 percent and around half of them will be in the 4-6 percent range, as most drugmakers have pledged to keep their price increases below 10 percent a year due to pressure from patients and politicians.

Donald Trump nominates Dr Stephen Hahn as next FDA Commissioner

The US FDA could be set to receive its next long-term Commissioner after the White House revealed President Donald Trump’s top pick to lead the regulatory agency.

Dr Stephen Hahn was announced as the Commander-in-Chief’s nomination for the role. Dr Hahn most recently served as the Chief Medical Executive at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas since May 2018, a patient care organisation employing around 21,000 staff; the firm also generates over $5 billion annually and conducts “the largest number of clinical trials in the United States”.

The November 2018 issue of Pharmafocus is available to read online now!

As the US continues to battle the demons in its healthcare system, Donald Trump looks like he may finally make good on his numerous and repeated promises to bring down drug prices, as well as bring  tangible action to the ongoing opioid crisis.

Since announcing a state of emergency over the latter crisis last year, the President has not been seen to attempt to affect any change on the issue, but hopes are high with the recent signing of a bipartisan bill which includes 200 provisions to tackle it, including partnerships with JJ&J, Facebook, Amazon and Google.

Novartis follows Pfizer's lead, pledges no price hikes in 2018

Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the prices of 100 of its products since the beginning of the year, Novartis has followed suit, pledging to freeze any increases in its own pricing until the end of the year.

Trump forces Pfizer to back down and delay price hikes until 2019

Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the President’s threats to crack down on drug prices and raised the price of 100 of its drugs, the firm has confirmed it will delay planned price hikes until the beginning of next year.

Unfazed by Trump, Pfizer hikes prices for 100 of its drugs

After a campaign full of not-so-veiled threats directed at the pharma industry, and a presidency which has so far failed to make good on those threats, US President Donald Trump finally revealed his plans to combat runaway drug prices and stop the industry “getting away with murder” earlier this month.

Pharma unfazed by Trump price-reduction proposals

IMAGE: Michael Vadon

President Trump’s speech on Friday afternoon had been long-anticipated, ever since he was elected and then hammered the pharma industry with talk over how it was “getting away with murder”.

The moment of truth arrived on how drastically Trump would target the industry and the answer turned out to be only in minor ways.

Trump’s rhetoric was still fierce, “The drug lobby is making an absolute fortune at the expense of American consumers – no industry spends more on lobbying than the pharmaceutical health products industry.”

Novartis’ $1.2m payment to Trump’s lawyer raises more questions than answers

Novartis payment to President Trump’s personal lawyer, Michael Cohen, had seemed fairly odd from the beginning – with many asking the same question, what was the company paying for?

In a statement, it tried to clarify why a payment as large as $1.2 million, up from the $400,000 previously revealed, over the course of the year was made to the lawyer, who has no background in healthcare, and his consultancy firm, Essential Consultants.

Novartis caught in the Stormy Daniels affair, after huge payment to Trump's lawyer

Michael Cohen. IMAGE: IowaPolitics.com

Novartis has suddenly found itself embroiled in the Stormy Daniels affair, after the lawyer representing her, Michael Avenatti, included the Basel-based pharma company in a series of payments made to a company set up by President Trump’s personal lawyer, Michael Cohen.

Avenatti revealed that Novartis had made four payments of $99,980, with the payments ending in January – not long before CEO Vas Narasimhan met with Trump in February.

Trump’s drug pricing reforms lack bite

IMAGE: Wikipedia/Gage Skidmore

President Trump’s rhetoric leading up to his election had the pharmaceutical industry very worried – his often quoted line about drug companies “getting away with murder” was followed by the suggestion that he wanted to “bring our prices down to what other countries are paying”.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches